The synthetic peptides have the sequence: [RrA\ A2, A6, A8, A11, A12, A15, A20, A21, A22, Nle27, A28, A29, A30]hGH-RH(1 -30)-R2 (SEQ ID NO: 1 ) wherein R1 is Ac, Tfa, or is absent, A1 is Tyr, Dat, or N-Me-Tyr, A2 is Ala, D-Ala, Abu, or D-Abu, A6 is Phe or Fpa5, A8 is Asn, Ala, Gin, Thr, or N-Me-Ala, A11 is Arg, His, or Har, A12 is Orn, or Lys(Me)2, A15 is Abu or Ala A20 is Arg, His, or Har, A21 is Orn, or Lys(Me)2, A22 is Leu, or Orn, A28 is Ser, or Asp, A29 is Arg, Har, Agm, D-Arg, or D-Har, A30 is Arg, Agm, Ada, Amc, Aha, Apa, Har, D-Arg, D-Har, Gab, Gin, D-GIn, Gin-Gab, D-Gln-Gab, or is absent, R2 is -NH2, -OH, -NHR2, -N(R2)2, or -OR2, in which R2 is any of C1-12 alkyl, C2-12 alkenyl, or C2-12 alkinyl, provided that if A29 is Agm then A30 and R2 are absent A1 is N-Me-Tyr only, and pharmaceutically acceptable salts thereof.Los péptidos sintéticos tienen la secuencia: [R1-A1, A2, A6, A8, A11, A12, A15, A20, A21, A22, N1e27, A28, A29, A30]hGH-RH(1-30)-R2 (SEQ ID NO: 1) en donde R1 es Ac, Tfa, o se encuentra ausente, A1 es Tyr, Dat o N-Me-Tyr, A2 es Ala, D-Ala, Abu o D-Abu, A6 es Phe o Fpa5, A8 es Asn, Ala, Gln, Thr o N-Me-Ala, A11 es Arg, His o Har, A12 es Orn o Lys(Me)2, A15 es Abu o Ala, A20 es Arg, His o Har, A21 es Orn o Lys(Me)2, A22 es Leu u Orn, A28 es Ser o Asp, A29 es Arg, Har, Agm, D-Arg o D-Har, A30 es Arg, Agm, Ada, Amc, Aha, Apa, Har, D-Arg, D-Har, Gab, Gln, D-Gln, Gln-Gab, D-Gln-Gab o se encuentra ausente, R2 es -NH2, -OH, -NHR2, -N(R2)2 u -OR2, en el cual R2 es cualquiera de alquilo C1-12, alquenilo C2-12 o alquinilo C2-12, con la condición de que si A29 es Agm entonces A30 y R2 se encuentran ausentes, A1 es sólo N-Me-Tyr, y sales farmacéuticamente aceptables de los mismos.
